Summary
Over a period of 4 years, 241 patients with advanced cancer were treated with mecaphane alone in 11 hospitals. Effective objective responses were obtained in 100 patients (41.4%). The response was most conspicuous in chronic granulocytic leukemia, with remission in 37 of 40 patients; in Hodgkin's disease and lymphosarcoma response rates were 60% and 47.3%, respectively. Mecaphane had an analgesic action in metastatic osteolytic bone cancer, and two patients with such metastases even attained recalcification of the osteolytic destructive lesions.
The common toxic manifestations of mecaphane were leukopenia (33.6%), gastrointestinal upsets (28.2%), and thrombocytopenia (12.8%).
It is concluded, therefore, that mecaphane could be a good antitumor agent in clinical use. It is less expensive and can be taken orally. Further trials of this drug are recommended.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bai-chuan Pan (1962) Scientia Sinica 11:483
Criteria of Response to Cancer Chemotherapy (1965) Proceedings of the Second National Symposium on Cancer Research, Shanghai, China, Chinese edn
Criteria of Response to Leukemia (1964) Tianjin Medical Journal [Transfusion and Hematology Supplemental Journal]. Chinese edn 2:158
Rui-ting Chen (1960) Acta Pharmaceutica Sinica, Chinese edn 8:217
Zhiyi Zhang (1965) Clinical trial (Phase 1) of Mecaphane (analysis of 80 cases). In: Proceedings of the Second National Symposium of Cancer Research (Chinese edn). Shanghai, China
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhang, Z., Yu, L., Sun, Z. et al. Clinical studies on the antitumor action of mecaphane. Cancer Chemother. Pharmacol. 6, 155–159 (1981). https://doi.org/10.1007/BF00262336
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00262336